Husam Issa, MD
Infectious Disease · Webster, TXNPI 1821064304
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,435 of the $41,099 with a category attached, or 86.2%. AbbVie accounts for 81.3% of it on its own, with 17 other manufacturers making up the rest. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $313.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- Merck$6K
- Gilead$483
- Abbott$299
- Viiv Healthcare Company$176
- Johnson & Johnson$165
- plus $692 from 12 others
Across 41 payments — averaging $16,815 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$374K
- Pfizer$150K
- First Wave Biopharma, Inc.$150K
- Grifols Shared Services North America, Inc.$16K
What the payments were for
- Speaking & faculty fees$35,43586%
- Travel & lodging$1,7044%
- Food & beverage$3,96010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $33,426 |
| Merck | 10 | $5,857 |
| Gilead | 18 | $483 |
| Abbott | 2 | $299 |
| Viiv Healthcare Company | 9 | $176 |
| Johnson & Johnson | 2 | $165 |
| Insmed, Inc. | 8 | $164 |
| Mylan Specialty L.p. | 4 | $162 |
| Melinta Therapeutics, LLC | 6 | $87 |
| Paratek Pharmaceuticals, Inc. | 2 | $58 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $53 |
| Exelixis Inc. | 1 | $43 |
| Genentech USA, Inc. | 1 | $24 |
| Shionogi Inc | 1 | $24 |
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Inari Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DALVANCE$19,947
- EMBLAVEO$6,950
- ZERBAXA$5,709
- AVYCAZ$5,500
- TEFLARO$200
- Confirm Rx$155
- Allure Quadra RF CRT Pacemaker$145
- Yupelri$125
- XARELTO$102
How this compares
$41,099 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 77 | $317,172 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 23 | $87,081 |
| DalvanceDalbavancin Hcl | 15 | $73,048 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $62,465 |
| Daptomycin | 43 | $28,572 |
| ErtapenemErtapenem Sodium | 32 | $13,804 |
| Meropenem | 52 | $9,312 |
| CeftriaxoneCeftriaxone Sodium | 34 | $6,073 |
| Cefepime Hcl | 20 | $3,930 |
| Cephalexin | 33 | $2,854 |
| Methenamine Hippurate | 14 | $2,063 |
| Doxycycline Monohydrate | 27 | $1,619 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 41 | $1,368 |
| Cefazolin Sodium | 15 | $1,082 |
| Sodium Chloride0.9 % Sodium Chloride | 11 | $1,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $483 | $379,63791 claims |
| AbbVieDalvance | $33,426 | $73,04815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Webster
- Elizabeth RaceDallas$1.5M
- Ogechika AlozieEl Paso$834K
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Cedric SpakFort Worth$427K
- Ben BarnettHouston$424K
- Uriel SandkovskyDallas$320K
- Amar SafdarHouston$284K
- Roger BedimoDallas$269K
- Miguel Sierra-HoffmanVictoria$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.